Registered number |
Registered number: | |||||||
Balance Sheet | |||||||
as at |
|||||||
Notes | 2022 | 2021 | |||||
£ | £ | ||||||
Fixed assets | |||||||
Tangible assets | 3 | ||||||
Investments | 4 | ||||||
Current assets | |||||||
Stocks | |||||||
Debtors | 5 | ||||||
Cash at bank and in hand | |||||||
Creditors: amounts falling due within one year | 6 | ( |
( |
||||
Net current liabilities | ( |
( |
|||||
Total assets less current liabilities | ( |
( |
|||||
Creditors: amounts falling due after more than one year | 7 | ( |
( |
||||
Provisions for liabilities | ( |
- | |||||
Net liabilities | ( |
( |
|||||
Capital and reserves | |||||||
Called up share capital | |||||||
Profit and loss account | ( |
( |
|||||
Shareholders' funds | ( |
( |
|||||
Mohammad Arsalaan Khan | Jaykumar Pradyuman Jani | Anil Kumar Sharma | |||||
Director | |||||||
Approved by the board on |
|||||||
Notes to the Accounts | ||||||||
for the year ended |
||||||||
1 | Accounting policies | |||||||
Basis of preparation | ||||||||
Going concern | ||||||||
The company has support from the shareholders for any funding requirments. The directors have confirmed continued support and consider the company retains sufficient working capital to continue trading for the foreseeable future. They continue to believe that the going concern basis of accounting is appropriate in preparing the financial statements. | ||||||||
Turnover | ||||||||
Research and development | ||||||||
Research and development expenditure is written off to the profit and loss account in the year in which it is incurred. | ||||||||
Tangible fixed assets | ||||||||
Freehold buildings | 4% straight line | |||||||
Fixture and fittings | 25% reducing balance | |||||||
Plant and machinery | 25% reducing balance | |||||||
Investments | ||||||||
Stocks | ||||||||
Debtors | ||||||||
Creditors | ||||||||
Taxation | ||||||||
Provisions | ||||||||
Foreign currency translation | ||||||||
Pensions | ||||||||
2 | Employees | 2022 | 2021 | |||||
Number | Number | |||||||
Average number of persons employed by the company | ||||||||
3 | Tangible fixed assets | |||||||
Land and buildings | Plant and machinery etc | Total | ||||||
£ | £ | £ | ||||||
Cost | ||||||||
At 1 January 2022 | ||||||||
Additions | - | |||||||
At 31 December 2022 | ||||||||
Depreciation | ||||||||
At 1 January 2022 | ||||||||
Charge for the year | ||||||||
At 31 December 2022 | ||||||||
Net book value | ||||||||
At 31 December 2022 | ||||||||
At 31 December 2021 | ||||||||
4 | Investments | |||||||
Investments in | ||||||||
subsidiary | ||||||||
undertakings | ||||||||
£ | ||||||||
Cost | ||||||||
At 1 January 2022 | ||||||||
At 31 December 2022 | ||||||||
5 | Debtors | 2022 | 2021 | |||||
£ | £ | |||||||
Trade debtors | ||||||||
Amounts owed by group undertakings and undertakings in which the company has a participating interest | ||||||||
Other debtors | ||||||||
6 | Creditors: amounts falling due within one year | 2022 | 2021 | |||||
£ | £ | |||||||
Bank loans and overdrafts | ||||||||
Trade creditors | ||||||||
Taxation and social security costs | ||||||||
Other creditors | ||||||||
Directors loan account | 4,342,588 | 5,284,006 | ||||||
7 | Creditors: amounts falling due after one year | 2022 | 2021 | |||||
£ | £ | |||||||
Bank loans | ||||||||
8 | Related party transactions | 2022 | 2021 | |||||
£ | £ | |||||||
Natlip Limited | ||||||||
Common director | ||||||||
Included within other creditors is an amount payable to Natlip Limited of: | 3,440,900 | 3,440,900 | ||||||
Abhaya Limited | ||||||||
Common director | ||||||||
Included within other creditors is an amount payable to Abhaya Limited of: |
1,841,868 | 1,841,868 | ||||||
Kinedexe Limited | ||||||||
Common director | ||||||||
Turnover includes fee charged to Kinedexe Limited of: | 23,055 | 6,640 | ||||||
Included within other creditors is an amount due to Kinedexe Limited of: | 1,030,159 | 1,078,706 | ||||||
ACE Laboratories Limited | ||||||||
Common director | ||||||||
During the year the company purchases goods and services from ACE Laboratories Limited of: |
- | 99,500 | ||||||
Included within trade creditors is an amount payable to ACE Laboratories Limited of: |
- | 354,561 | ||||||
Included within other creditors is an amount payable to ACE Laboratories Limited of: |
104,744 | 154,136 | ||||||
Arise Pharma Ltd | ||||||||
Common director | ||||||||
Included within other creditors is an amount payable to Arise Pharma Ltd of: | 492,047 | 181,746 | ||||||
Jaj Pharma Limited | ||||||||
Common director | ||||||||
Included with other creditors is an amount payable to Jaj Pharma Limited of: | 614,000 | 628,000 | ||||||
Liqmeds Limited | ||||||||
Common director | ||||||||
Turnover includes the work carried out for Liqmeds Limited of: | 720,333 | 2,197,222 | ||||||
Included within other creditor is an amount payable to Liqmeds Limited of: | 887,324 | 1,388,000 | ||||||
Liqmeds Worldwide Limited | ||||||||
Common director | ||||||||
Turnover includes the work carried out for Liqmeds Worldwide Limited of: |
2,650,000 | 1,750,000 | ||||||
Included within trade debtors is an amount receivable from Liqmeds Worldwide Limited: | 833,975 | 415,082 | ||||||
L M Manufacturing India Private Limited - a company incorporated in India |
||||||||
Common director | ||||||||
During the year the company received goods and services from L M Manufacturing India Private Limited of: |
518,282 | 285,000 | ||||||
Included within amount receivable from group undertakings is an amount receivable from L M Manufacturing India Private Limited of: | 727 | 6,707 | ||||||
Wave Pharma Limited | ||||||||
Common director | ||||||||
Included within other creditors is an amount payable to Wave Pharma Ltd of: | 229,123 | 177,323 | ||||||
Wave Pharma Regulatory Services Ltd | ||||||||
Common director | ||||||||
Included within other debtor is an amount receivable from Wave Pharma Regulatory Services Ltd of: |
58,346 | 58,346 | ||||||
Jaykumar Pradyuman Jani | ||||||||
Director of the company | ||||||||
Included within directors loan account is an amount payable to Mr Jaykumar Pradyuman Jani of: |
78,611 | 399,339 | ||||||
Mohammad Arsalaan Khan | ||||||||
Director of the company | ||||||||
Included within directors loan account is an amount payable to Mr Mohammad Arsalaan Khan of: |
110,557 | 120,697 | ||||||
Romana Khan | ||||||||
Related to the director of the company | ||||||||
Included within directors loan account is an amount payable to Romana Khan of: |
- | 600,000 | ||||||
Jagjeet Kaur Ahluwalia | ||||||||
Director of the company | ||||||||
Included within directors loan account is an amount payable to Mrs Jagjeet Kaur Ahluwalia of: | 3,970,000 | 3,970,000 | ||||||
Anil Kumar Sharma | ||||||||
Director of the company | ||||||||
Included within directors loan account is an amount payable to Mr Anil Kumar Sharma of: | 183,420 | 183,420 | ||||||
Eiman Pharma Limited | ||||||||
Common director | ||||||||
Included within other creditors is an amount payable to Eiman Pharma limited of: | 2,009,000 | 1,400,000 | ||||||
JSM Innovations Limited | ||||||||
Common director | ||||||||
Included within other creditors is an amount payable to JSM Innovations Limited of: | 957,092 | 957,092 | ||||||
UDAJ Limited | ||||||||
Common director | ||||||||
Included within other creditors is an amount payable to UDAJ Limited of: | 30,000 | 30,000 | ||||||
Medsolutions (Europe) Limited | ||||||||
Included within other debtor is an amount receivable from Medsolutions (Europe) Limited of: | 6,797 | - | ||||||
9 | Controlling party | |||||||
10 | Other information | |||||||
L M MANUFACTURING LIMITED is a private company limited by shares and incorporated in England. Its registered office is: | ||||||||
Sandretto Building | ||||||||
Cavalry Hill Industrial Park | ||||||||
Weedon | ||||||||
Northampton | ||||||||
NN7 4PP |